← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Onevax, Llc
Gainesville, FL
$2,680,345
Total funding
9
Grants
Funding over time
peak $989.3K · FY2013–20$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,680,345 · 9
By mechanism
R43$1,317,604 · 6
R44$989,307 · 1
R21$255,617 · 1
R41$117,817 · 1
Investigators at Onevax, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.$989,307
R44 · FY2020 · DK
A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes$238,328
R43 · FY2017 · AI
Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 Diabetes$235,720
R43 · FY2017 · AI
Polymeric biomaterial-based microparticle vaccine for amelioration of Type 1 diab$226,205
R43 · FY2013 · DK
Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes$221,331
R43 · FY2018 · AI
A novel biomaterial-based therapy to prevent type 1 diabetes$200,212
R43 · FY2014 · DK
Biomaterial-Based Delivery of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes$195,808
R43 · FY2018 · DK
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes$127,877
R21 · FY2017 · AI
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes$127,740
R21 · FY2018 · AI
Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes$117,817
R41 · FY2017 · AI